The results showed a consistent advantage for the combination, and that advantage became more pronounced at higher weight loss thresholds, precisely where GLP-1 therapy tends to be most clinically meaningful: At a 20% weight loss threshold, 45% of women in the combination group achieved this level of loss, compared to 24% in the GLP-1 alone group
I feel nicely anonymous
Who Should Be Cautious About Quick-Access GLP-1 Providers If any of the following apply to you, working with a physician who knows your full history matters more than convenience: You have a history of thyroid tumors or a family history of medullary thyroid cancer You have gallbladder disease or a history of pancreatitis You're managing diabetes and taking other blood-sugar-affecting medications You have kidney disease or reduced kidney function You're on multiple medications that could interact These aren't reasons to avoid GLP-1 medications altogether they're reasons to start them under the care of a doctor who can actually monitor for them
Simply fax it or email it
In this small cohort, some of the participants ( n = 7) completed 3 wk of up-titration with the dual GLP1/glucagon agonist SAR425899, and all responded to treatment with blood glucose lowering and weight reduction, regardless of exhibiting a wide range of GLP1R density in the pancreas ( 12 )
Medication adherence is closely linked with treatment outcomes in chronic conditions
